title: Serotonin 5-HT1A Receptors and Antipsychotics - An Update in Light of New Concepts and Drugs.
abstract: Schizophrenia is characterised by positive, negative, cognitive, depressive and anxiety symptoms. Over the last decades a number of novel treatment strategies with better clinical efficacy and scope, but with lower side-effect profiles have been developed. These have significantly improved the management and prognosis of the disease. Of these approaches, modulation of the serotonergic receptor system is a common, recurring, theme; particularly the use of 5-HT1A receptor agonism as part of or adjunct to existing therapies. Here we review data exploring the utility of 5-HT1A receptor agonists for extending the actions of antipsychotic agents, while limiting their side-effect profile. Notably, interest has grown concerning 5-HT1A receptor activation in schizophrenia because of the development of novel antipsychotics, such as lurasidone and cariprazine, the characterisation of 5-HT1A receptor polymorphisms in schizophrenia patients and the possible beneficial influence of 5-HT1A agonists on neurogenesis.
authors.affiliation: Brains On-Line, de Mudden 16, 9747AW Groningen, The Netherlands. andrew.mccreary@brainsonline.org.
authors.forename: Andrew C
authors.initials: AC
authors.lastname: McCreary
authors.forename: Adrian
authors.initials: A
authors.lastname: Newman-Tancredi
mesh_terms: D014150:Antipsychotic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D006801:Humans; D019964:Mood Disorders / Q000188:drug therapy / Q000503:physiopathology; D044282:Receptor, Serotonin, 5-HT1A / Q000187:drug effects* / Q000502:physiology; D012559:Schizophrenia / Q000188:drug therapy / Q000503:physiopathology; D059326:Serotonergic Neurons / Q000187:drug effects / Q000502:physiology
chemical_list: D014150:Antipsychotic Agents; D044282:Receptor, Serotonin, 5-HT1A